ADMA Biologics, Inc. (ADMA) Institutional Ownership & Insider Trading

322 institutions reported holding ADMA Biologics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 16 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ADMAADMA Biologics, Inc.Follow ADMA — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 2.4B
P/E TTM: 15.3
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

322 institutions held 91.8% of the shares. Across filers that reported both quarters, shares held changed -3.0%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	322	206	-3.0%	85	40	141	70
Mar 26	351	211	-4.5%	124	55	102	56
Dec 25	350	220	-0.1%	130	40	108	53
Sep 25	354	217	+3.9%	88	54	149	56
Jun 25	363	211	+1.9%	141	69	102	46
Mar 25	342	204	+1.1%	118	54	98	30
Dec 24	316	204	-3.6%	115	56	94	49
Sep 24	301	208	+1.8%	92	81	89	37

ADMA Biologics, Inc. — questions

Who owns ADMA Biologics, Inc. stock?: 322 institutions reported ADMA Biologics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (17.1%), STATE STREET CORP (7.6%), VANGUARD CAPITAL MANAGEMENT LLC (4.5%).
Are ADMA Biologics, Inc. insiders buying or selling?: 16 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from ADMA Biologics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.